Edition:
United Kingdom

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

3.40USD
7:48pm GMT
Change (% chg)

$-0.10 (-2.99%)
Prev Close
$3.51
Open
$3.49
Day's High
$3.54
Day's Low
$3.40
Volume
75,467
Avg. Vol
105,043
52-wk High
$9.69
52-wk Low
$3.05

Latest Key Developments (Source: Significant Developments)

Pieris Pharmaceuticals Q2 Earnings Per Share $0.00
Thursday, 9 Aug 2018 

Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 EARNINGS PER SHARE $0.00.Q2 EARNINGS PER SHARE VIEW $-0.01 -- THOMSON REUTERS I/B/E/S.PIERIS PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $151.7 MILLION AS OF JUNE 30, 2018, COMPARED TO $82.6 MILLION AS OF DEC 31, 2017.QTRLY REVENUES $11.7 MILLION VERSUS $1.9 MILLION.  Full Article

Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Astrazeneca Plc ::PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING.  Full Article

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors.Pieris Pharmaceuticals Inc - ‍Geraghty replaces Chau Khuong, who is stepping down from board​.  Full Article

Pieris Pharmaceuticals reports Q3 loss per share $0.16
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update.Q3 loss per share $0.16.Pieris Pharmaceuticals Inc - ‍cash and equivalents totaled $89.9 million as of September 30, 2017, compared to $29.4 million as of December 31, 2016​.  Full Article